LPA and familial hyperaldosteronism: Ongoing studies with RNA based therapies will establish whether specific lowering of Lp(a) of the order of 80% (Tsimikas et al., 2020b), or a mean reduction of 100 mg/dL (Burgess et al., 2018), confers improvement in cardiovascular outcomes in high risk individuals, but none of these trials are specifically being carried out in patients with FH.